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Background: Amitriptyline (AMI) is tricyclic antidepressant that has been widely used to manage various chronic
pains such as migraines. Its efficacy is attributed to its blockade of voltage-gated sodium channels (VGSCs).
However, the effects of AMI on the tetrodotoxin-resistant (TTX-r) sodium channel Nav1.9 currents have been unclear
to present.
Results: Using a whole-cell patch clamp technique, this study showed that AMI efficiently inhibited Nav1.9 currents
in a concentration-dependent manner and had an IC50 of 15.16 μM in acute isolated trigeminal ganglion (TG)
neurons of the rats. 10 μM AMI significantly shifted the steady-state inactivation of Nav1.9 channels in the
hyperpolarizing direction without affecting voltage-dependent activation. Surprisingly, neither 10 nor 50 μM AMI
caused a use-dependent blockade of Nav1.9 currents elicited by 60 pulses at 1 Hz.
Conclusion: These data suggest that AMI is a state-selective blocker of Nav1.9 channels in rat nociceptive
trigeminal neurons, which likely contributes to the efficacy of AMI in treating various pains, including migraines.
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Amitriptyline (AMI) is a tricyclic antidepressant that has
also been widely used to treat different types of chronic
pain, such as migraines and diabetic neuropathic pain
[1,2]. The antidepressant action is known to inhibit the
presynaptic reuptake of norepinephrine and/or serotonin
and thus increase concentrations of these neurotrans-
mitters at the synaptic cleft [3,4]. However, its analgesic
efficacy is poorly correlated with its antidepressant ac-
tion because antidepressants are analgesic in patients
with chronic pain and no concomitant depression [5]
and selective serotonin reuptake inhibitors (SSRIs) are
typically ineffective in treating neuropathic pain [6]. Al-
though the mechanism underlying AMI analgesic action
is not fully understood, AMI inhibits voltage-gated so-
dium channels (VGSCs) to reduce the generation and
conduction of action potentials in sensory neurons, even
more than the local anesthetic bupivacaine, which could
in partly explain its efficacy in relieving pain [7-9].* Correspondence: yushengyuan301@yahoo.com
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reproduction in any medium, provided the orVGSCs Nav1.1-Nav1.9 play critical roles in electrical
signaling through action potential generation and propa-
gation in the nervous system; some specific channel
subtypes have been implicated in a number of chronic
pain conditions. According to their relative sensitivity to
tetrodotoxin (TTX), VGSCs are classified as TTX-
sensitive (TTX-s) channels (Nav1.1-Nav1.4, Nav1.6 and
Nav1.7) and TTX-resistant (TTX-r) channels (Nav1.5,
Nav1.8 and Nav1.9)[10]. Na
+ currents blocked by AMI
were first found in studies of AMI toxicity in the heart,
which was supported by a study in which AMI potently
inhibited recombinat cardiac hNav1.5 currents [11]. AMI
almost completely inhibited veratridine- or scorpion
toxin-evoked efflux of endogenous dopamine (DA) and
gamma-aminobutyric acid (GABA) from rat striatal
slices by its blockade of Na+ influxes and significantly
blocked Na+ currents in a use-dependent manner in
cultured GH3 cells [12]. In bovine adrenal chromaffin
cells, AMI blocked Na+ currents and caused a hyperpo-
larizing shift of the steady-state inactivation curve [13].
In cultured rat cortical neurons, AMI not only altered
the activation and steady-state inactivation curves of
TTX-s Na+ currents toward hyperpolarization but also
decreased mRNA expression of Nav1.1, Nav1.2 andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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r Na+ currents were reduced by AMI in a dose- and
holding potential-dependent manner in rat dorsal root
ganglion (DRG) neurons [15]. Moreover, regardless of
the heterologous expression of Nav1.8 in ND7/23 cells
or hNav1.7 in HEK293 cells, Na
+ currents were effect-
ively inhibited by AMI in concentration-, use- and
state-dependent manners [16]. Collectively, these
findings provided evidence that AMI could block a
variety of VGSC currents in different manners in
different cells.
To our knowledge, the effects of AMI on Nav1.9 cur-
rents in any cell types have not been reported, although
AMI has been shown to dramatically block TTX-r Na+
channels in rat trigeminal ganglion (TG) neurons [17] as
well as in rat DRG neurons [15]. There are at least
two subtypes of TTX-r Na+ channels, i.e., Nav1.8 and
Nav1.9, which differ in many respects, such as channel
activation/inactivation kinetics and pharmacological
properties. Nav1.8 channels are activated at relatively
depolarized potentials (around −40 mV) and inactivated
more slowly than TTX-s Na+ channels [18,19], similar to
the classic TTX-r Na+ channels [20]. Nav1.9 channel ac-
tivation occurs at hyperpolarized potentials (around
−70 mV, close to the resting membrane potential), and
its inactivation is ultraslow compared to Nav1.8 and
TTX-s Na+ channels [21]. As a result, Nav1.9 channel
activation and inactivation are widely overlapping
around the resting potential, leading to the production
of a persistent current [22,23]. Nav1.8 channels contrib-
ute to the majority of the depolarizing inward current of
action potentials in neurons in which it is expressed
[24,25], whereas Nav1.9 channels modulate resting mem-
brane potential and responses to subthreshold stimuli
and to depolarization, which could in turn amplify
depolarizing inputs and increase excitability of nocicep-
tive sensory neurons [26]. Both channels are remarkably
specifically expressed in small-diameter TG and DRG
neurons with thinly myelinated (Aδ) or unmyelinated
axons and are likely to be implicated in the molecular
mechanisms of nociception and pain [27-30].
Recently, we found that the systemic administration
of AMI significantly alleviated nociceptive pains in-
duced by electrical stimulation of the dura mater
surrounding the superior sagittal sinus (SSS) in animal
models of migraines [31]. Furthermore, AMI pro-
foundly blocked Nav1.8 currents in concentration-,
use- and state-dependent manners in acute isolated
TG neurons (unpublished data). In the present study,
the effects of AMI on the biophysical properties of
Nav1.9 currents in acute isolated TG neurons were
examined using whole-cell patch clamp recordings,
which may provide a new molecular basis for the
analgesic action of AMI.Results
Recording of Nav1.9 currents in acute isolated TG neurons
In the present study, whole-cell voltage recordings were
only performed on small-sized TG neurons (15–23 μm),
which served as nociceptors [32]. Of 209 total neurons,
125 that showed stable recording conditions before and
after compound application and washout were included
for further study. According to a previous report
[19,23], a voltage-clamp protocol in which neurons
hyperpolarized over the course of 700 ms in response to
the application of −100 mV before voltage steps applied
(see protocol in Figure 1A) was used to elicit TTX-r
Nav1.9 currents in the presence of 500 nM TTX. This
step-wise protocol activated Nav1.9 currents first at
approximately −60 mV, followed by Nav1.8 currents
from −30 to −20 mV. Although Nav1.8 currents were
greatest, the presence of Nav1.9 produced a prominent
shoulder (around −35 mV) on the current/voltage (I/V)
curve (Figure 1C), which before performing further ex-
periment was examined in every TG neuron to exclude
cells that do not express Nav1.9. Therefore, TTX-r Na
+
currents at voltages ranging from −60 to −35 mV were
mainly mediated by Nav1.9 channels, and the single volt-
age step at −35 mV was chosen to elicit the peak ampli-
tude of Nav1.9 currents. The above properties are in
agreement with Nav1.9 currents that were previously
characterized in rat DRG neurons [19,23]. To observe
the stabilization of its peak amplitude, Nav1.9 currents
elicited by −35 mV were measured after whole-cell
stimulation was performed. As shown in Figure 1E, the
peak amplitude of Nav1.9 currents was relatively stable
from 5 to 15 min (n = 8). All of our subsequent experi-
ments were recorded during this time.
Effect of different concentrations of AMI on Nav1.9
currents
A single voltage step protocol was used to evaluate the
effect of AMI on Nav1.9 currents in rat TG neurons
(Figure 2A). AMI caused concentration-dependent de-
creases in peak amplitudes of Nav1.9 currents, and these
effects were partially reversed when AMI was washed
away (Figure 2B). AMI inhibition was significant at all
the following concentrations except 0.1 μM: 0.1 μM
(1.01 ± 2.98%; n = 9, P > 0.05 ), 1 μM (15.84 ± 2.42%;
n = 7, P < 0.05), 5 μM (37.11 ± 3.51%; n = 9, P < 0.05),
10 μM (42.19 ± 3.28%; n = 8, P < 0.05), 50 μM (65.28 ±
7.41%; n = 9, P < 0.05) and 100 μM (81.00 ± 5.20%; n = 6,
P < 0.05 ) (Figure 2C). Fitting to the Hill equation
revealed a half-blockade (IC50) at 15.16 μM with an
apparent Hill coefficient of 0.64.
Effect of AMI on Nav1.9 channel activation
To examine the effects of AMI on channel activation
kinetics, Nav1.9 currents were evoked by hyperpolarizing
Figure 1 Whole-cell patch clamp recording of TTX-r Nav1.9 currents in acute isolated TG neurons. A: The protocol to elicit Nav1.9 currents,
starting from a holding potential of −70 mV to the prepulse potential of −100 mV, and then to the voltage steps ranging from −80 to −20 mV in
increments of +5 mV. B: Representative recordings of the Nav1.9 currents elicited by a series of voltage steps using the protocol in (A). C:
Current/voltage (I/V) relationship of Nav1.9 channels with the protocol in (A). Each point was normalized to the amplitude of Nav1.9 currents at
−35 mV (n = 9) D: The protocol of a single pulse from −100 mV to −35 mV. E: Peak amplitudes of Nav1.9 currents elicited by a single pulse at
−35 mV between 5 and 15 min after whole cell activation was performed. The currents were stable during the recording time in all cells (n = 8).
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the application of voltage steps ranging from −80 to
−20 mV in increments of +5 mV (Figure 3A). Figures 3B
and 3C show typical I/V relationships before and after
perfusion with 10 μM AMI, respectively. The I/V curveFigure 2 Effects of AMI on TTX-r Nav1.9 currents, which were measur
The protocol of a single voltage step at −35 mV. B: Representative recordin
perfusion with 10 μM AMI. C: Concentration-dependent inhibition of AMI o
to the control (n = 6–9).was shifted upward after exposure to 10 μM AMI
(Figure 3D). However, the voltage-activation curve that
was fitted to the Boltzman equation only exhibited a
slightly hyperpolarization after perfusion with 10 μM
AMI (Figure 3E). The voltage generating half-maximaled using whole-cell patch clamp recordings from TG neurons. A:
gs of the Nav1.9 currents elicited by a single pulse before and after
n Nav1.9 currents with the protocol in (A). Each point was normalized
Figure 3 Effect of 10 μM AMI on the voltage-activation relationship of TTX-r Nav1.9 currents. A: The protocol to elicit Nav1.9 currents
starting from a holding potential of −70 mV to the prepulse potential of −100 mV, and the voltage steps ranging from −80 to −20 mV in
increments of +5 mV. B and C: Representative recordings of the Nav1.9 currents elicited by a series of voltage pulses using the protocol in (A)
before and after perfusion with 10 μM AMI, respectively. D: The effect of 10 μM AMI on the I/V curves of Nav1.9 currents. Each point was
normalized to the respective I-35 mV currents (n = 11). E: Effect of 10 μM AMI on the voltage-activation relationships of Nav1.9 currents. Each point
was normalized to its respective I-35 mV of Nav1.9 currents (n = 11).
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−50.36 ± 0.53 mV after perfusion with 10 μM AMI
(n = 11, P > 0.05), and the slop factor k did not change
significantly (4.55 ± 0.43 before to 4.51 ± 0.47 after
perfusion with 10 μM AMI, P > 0.05).
Effect of AMI on Nav1.9 channel inactivation
To measure the steady-state inactivation of Nav1.9
channels, double-pulse protocols starting from a holding
potential of −70 mV were used. Conditioning pulses from
−110 mV to −35 mV were performed over 1 s to ensure
that Nav1.9 channels were entirely inactivated (Figure 4A).
Figures 4B and C show the recorded channel responses to
test pulses (the voltage step at −35 mV for 200 ms) before
and after exposure to 10 μM AMI, respectively. The
steady-state inactivation, fit to the Boltzmann equationexhibited a significant hyperpolarization (Figure 4D). Half-
maximal steady-state inactivation (V0.5inact) was −54.50 ±
0.77 mV before and −64.17 ± 1.09 mV after perfusion with
10 μM AMI (n = 11, P < 0.05), and there was no statistical
change in the slop factor k (8.47 ± 0.56 before to 8.86 ±
0.92 after perfusion with 10 μM AMI, P > 0.05).
Effect of AMI on use-dependent blockade of Nav1.9
channels
To study whether its channels could be blocked by AMI
in use-dependent manner, Nav1.9 channels were acti-
vated at 1 Hz by 60 test pulses at −35 mV from a
hyperpolarized potential of −100 mV (Figure 5A). Treat-
ment with 10 μM AMI significantly reduced the peak
amplitude of Nav1.9 currents compared to those in the
absence of AMI (Figure 5B); however, AMI had little
Figure 4 Effect of 10 μM AMI on the steady-state inactivation relationship of TTX-r Nav1.9 currents. A: The protocol to elicit steady-state
inactivation of Nav1.9 currents starting from a holding potential of −70 mV, applying conditioning pulses ranging from −110 to −35 mV in
increments of +5 mV, and applying a test pulse at −35 mV. B and C: Representative recordings of the Nav1.9 currents elicited by a series of test
pulses using the protocol in (A) before and after exposure to 10 μM AMI, respectively. D: The effect of 10 μM AMI on the steady-state inactivation
relationship of Nav1.9 currents. Each point was normalized to its respective maximal Nav1.9 currents (n = 11).
Liang et al. Molecular Pain 2013, 9:31 Page 5 of 10
http://www.molecularpain.com/content/9/1/31effect on the use-dependence of Nav1.9 channels
(Figure 5C). The amplitude of the 60th Nav1.9 current
only slightly decreased to 94.29 ± 2.50% of the first
current during the 10 μM AMI perfusion, and no dif-
ference was observed when compared to control cur-
rents (97.13 ± 2.26%, n = 9, P > 0.05; Figure 5E). To rule
out the influence of the concentration on use-
dependent blockade, 50 μM AMI was used in a subse-
quent test. Similar to the 10 μM experiments, 50 μM
AMI had little effect on the use-dependence of Nav1.9
channels (93.65 ± 1.43% of the first one, n = 9; Figures 5D
and 5E). These results indicated that AMI did not
significantly contribute to the use-dependent block-
ade of Nav1.9 currents when stimulated by 60 pulses
at 1 Hz.Discussion
Although AMI has been widely reported to block some
subtypes of VGSCs, including Nav1.5, Nav1.7 and Nav1.8
[11,16], to our knowledge, this is the first report thatstudies the effects of AMI on TTX-r Nav1.9 channels in
TG neurons.
The present results showed that AMI efficiently
inhibited Nav1.9 channels in rat TG neurons in a
concentration-dependent manner and had an IC50 of
15.16 μM, consistent with previous findings that AMI
blocked TTX-r Na+ currents in rat TG neurons (IC50 of
AMI was 15.8 μM) [17]. In patients with depression or
neuropathic pain who receive daily doses of 10 to
300 mg AMI, plasma steady-state concentrations range
from 0.36 to 0.90 μM [33]. The concentrations of AMI
used in this study are higher than the clinically relevant
plasma concentrations. However, even at clinically rele-
vant concentrations between 0.1 and 1 μM, the peak Na+
currents were still decreased by approximately 1–15%.
However, the brain and plasma concentration ratios of
AMI observed in chronically treated rats were found to be
more than 20:1, which was similar to levels reported in
humans [34,35]. In this case, the IC50 value for Nav1.9
channels would be similar to the concentration of AMI
found in the brain: it is thus possible that Nav1.9 channels
Figure 5 Effect of 10 and 50 μM AMI on the use-dependent relationship of TTX-r Nav1.9 currents. A: The protocol of a single voltage step
at −35 mV. B, C and D: Representative recordings of the Nav1.9 currents elicited by 60 pulses at 1 Hz before and after perfusion with 10 and
50 μM AMI, respectively. E: The effect of 10 and 50 μM AMI on the use-dependent relationship of Nav1.9 currents. Each point was normalized to
the respective first Nav1.9 current (n = 9). F: The current at the 60th pulse normalized to the current of the first pulse, was not significantly
decreased after perfusion with 10 or 50 μM AMI compared to that of the controls (n = 9, P > 0.05).
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block both TTX-s and TTX-r Na+ channels in rat DRG
neurons by modulating Na+ channel activation and inacti-
vation kinetics [15], AMI produced only a prominent
hyperpolarizing shift in the steady-state inactivation
curves of Nav1.9 channels and had no significant effects
on the channel activation kinetics in rat TG neurons, in-
dicating that the binding of AMI to Nav1.9 channels
was state-dependent. This phenomenon was similar to
previous reports on the inhibition of TTX-r Na+ channels
in rat TG neurons [17]. The discrepancy in these findings
may be due to differences in tissue sources and the
experimental protocols.
Previous studies have shown that the blockade of
TTX-s and TTX-r Na+ channels and Nav1.8 channels by
local anesthetics and AMI is highly use-dependent
[16,36,37]. However, there was no use-dependent block-
ade in the presence of 10 or 50 μM AMI at 1 Hz stimu-
lation in this study. This use-dependent blockade wouldresult from the binding of an antagonist ligand to
inactivated channels that are more prevalent during re-
petitive stimulation and from the dissociation of the an-
tagonist from the inactivated states with a time constant
slower than the frequency of the pulses, which means
that use-dependent blockade arises from the slow
recovery of antagonist-bound channels due to an inter-
action between antagonist and inactivated states [16,37].
According to this hypothesis, the dissociation time con-
stant of AMI from inactivated Nav1.9 channels might be
faster than the frequency of the pulses (1 Hz) used in
this study. Clearly, only one frequency was tested in this
experiment; higher frequencies, such as 5, 10 or 20 Hz,
were not investigated due to limitations in the protocol,
in which the spent time of a single voltage step was ap-
proximately 900 ms (Figure 5A). These inconsistent
findings might also be explained by the presence of the
different binding sites. For example, local anesthetics
and AMI are known to block Nav1.8 channels in a use-
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which are located within the ion-conducting pore
[8,38,39]. Selective Nav1.8 channel blockers A-803467
and A-887826 do not cause use-dependent blockage and
were instead thought to recognize a binding site that is
distinct from the binding sites for use-dependent
blockers [40]. It was recently proposed that Nav1.9
currents exhibit ultraslow activation and inactivation
kinetics, which is likely the product of a substantially
different amino acid sequence, especially in the voltage-
sensing regions, compared to other Na+ channel subtypes
[22,41]. Therefore, further studies on the dissociation time
constant of AMI from the inactivated states of Nav1.9
channels will help address this issue.
In addition to having the effect on Nav1.9 currents in
the present study, AMI was also reported to inhibit
Nav1.8 channels heterologously expressed in ND7/23
cells in concentration- and use-dependent manners, and
to change activation and inactivation kinetics of Nav1.8
channels [16]. Similar results were also obtained from
our study on modulation of Nav1.8 channels by AMI in
TG neurons (unpublished data). Nav1.8 and Nav1.9
channels may be individually expressed or co-expressed
in the small diameter TG neurons, so the potential con-
tamination with Nav1.8 current and possible impact on
AMI behavior may be included in the present study, al-
though Nav1.8 and Nav1.9 currents can be distinguished
by the experimental protocols [19,23] and the I/V curve
which was examined in every TG neuron to validate
presence of Nav1.9. This study showed that AMI had no
effects on the activation kinetics and had no use-
dependent blockade of Nav1.9. However, it is well docu-
mented that AMI significantly changed the activation
kinetics and caused use-dependent blockade of Nav1.8
[16]. These results suggested that even if it had, it would
only a little the potential contamination with Nav1.8
current and a little impact on AMI behavior in the
present study.
Persistent subthreshold Na+ currents, carried primarily
by Nav1.9 channels that are expressed exclusively in
small nociceptive TG and DRG neurons [27-30], are
known to lessen spike threshold and eventually facilitate
maintained spiking [23,42]. The loss of Nav1.9-mediated
Na+ currents was associated with the inability of
neurons to generate a large variety of electrophysio-
logical behaviors, including subthreshold regenerative
depolarization, active hyperpolarizing responses, oscilla-
tory bursting discharges, plateau potentials and bistable
membranes [43]. In Nav1.9 knock-out mice, there is a
loss of persistent currents and blunted or missing pain
behaviors induced by complete Freund adjuvant (CFA),
carrageenan, formalin, and prostaglandin E2 (PGE2) [44]
or in response to inflammatory mediators, such as
bradykinin, serotonin, interleukin-1beta, and P2X3 andP2Y receptor agonists [45]. Consistently, antisense-based
Nav1.9 gene silencing in rats attenuated carrageenan-
induced heat and mechanical pain allodynia [46]. Re-
sponse to pain is relevant to the persistent currents, as
demonstrated by electrophysiological studies in isolated
primary sensory neurons, where inflammatory mediators
such as PGE2 and serotonin [44,47], as well as some se-
creted proteins (e.g., glial-derived neurotrophic factor
(GDNF) [48]), or activators of G protein pathways [26],
have been reported to increase Nav1.9 currents.
Migraines are the most common headache disorder
and affect more than 10% of the general population
[49,50]. Migraines are thought to arise from the activa-
tion and sensitization of the trigeminovascular system,
followed by the release of inflammatory mediators from
the trigeminal system, with a consequent vasodilation of
innervate intracranial blood vessels and generation of
neurogenic inflammation [51]. Such inflammation
causes hyperexcitability of TG neurons (peripheral
sensitization) and the second-order sensory neurons
(central sensitization) [52,53]. The above-mentioned
PGE2, interleukin-1 beta, and G protein-coupled P2X3
and P2Y receptors, which are known to functionally
regulate Nav1.9 channels during inflammation, have
also been closely linked to the pathophysiology of mi-
graines in a variety of experimental and clinical studies
[54-57]. In addition, immunohistochemical experi-
ments had shown that P2X3, bradykinin B2, and tran-
sient receptor potential vanilloid 1 (TRPV1) receptors
are highly co-localized with Nav1.9 channels in noci-
ceptor sensory neurons [45]. TRPV1 receptors have
been implicated as new therapeutic targets for the
treatment of migraines [58]. Although there is not a
direct link between migraines and Nav1.9 channels,
AMI has been widely used for the prophylactic treat-
ment of migraines and has demonstrated clear success
in clinical practice. These results were supported by
our findings that AMI efficiently blocked Nav1.9
currents, which might help, at least in part, understand
the mechanism underlying AMI efficacy in migraine
pain.
Conclusion
In summary, the present results demonstrate that AMI
is a state-selective blocker of Nav1.9 channels in noci-
ceptive trigeminal neurons, which likely contributes to
the analgesic action of AMI in various pains including
migraines.
Methods
Preparation of TG neurons
All experimental procedures were approved by the
Committee of Animal Use for Research and Education of
the Laboratory Animals Center of the Chinese PLA
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with the ethical guidelines recommended by the Inter-
national Association for the Study of Pain in conscious
animals [59]. Efforts were made to minimize the animals’
suffering. TG neurons from 7-day-old neonatal Sprague–
Dawley rats (The Academy of Military Medical Sciences,
Beijing, PR China) were prepared using a modified version
of a previously described method [60]. Briefly, rats were
deeply anesthetized by intraperitoneal injection of euthasol
(0.1 mg/kg) and decapitated. A pair of the TGs were rapidly
dissected from each animal, washed several times in ice-
cold Hank’s Balanced Salt Solution (HBSS; Life Technology,
MD), and then dissociated by mechanical disruption and
incubated in 2 mL HBSS containing 0.25% trypsin at 37°C
for 25 min. The tissues were washed twice in DMEM (high
glucose) (Hyclone, Logan, UT) and resuspended in DMEM
with 10% fetal bovine serum, 10% heat-inactivated horse
serum and 1% L-glutamine, and triturated with a flame-
polished Pasteur pipette to dissociate individual cells. Sub-
sequently, cells were plated onto poly-L-lysine-coated glass
coverslips (12 mm diameter) placed in 24-well plates, and
then maintained in a humidified atmosphere of 95% air and
5% CO2 at 37°C. The cells were used for recordings be-
tween 2 and 10 h after plating.
Patch clamp recordings
The whole-cell patch clamp recordings were performed
at room temperature; currents were measured with an
Axopatch-200B (Axon Instruments, Inc., Foster City,
CA, USA) and recorded with pClamp 8.2 software
(Axon Instruments, Inc., Foster City, CA, USA). The
output was digitized with a Digidata 1322A converter
(Axon Instruments, Inc., Foster City, CA, USA). Patch
pipettes were made by a two-step vertical puller
(Narishige Scientific Instrument Laboratory, Tokyo,
Japan; model PP-83) from borosilicate glass and had
resistances between 2 to 3 MΩ after perfusion of in-
ternal solution through the pipette. Cells in the glass
coverslip dishes were placed in a recording chamber and
visualized with the phase contrast microscopy on an
inverted microscope (Nikon, Tokyo, Japan). Currents
were recorded from small TG neurons (15–23 μm diam-
eter). Experiments were performed at a holding potential
of −70 mV for Nav1.9 currents. After gigaohm seal
formation and membrane disruption, the whole cell cap-
acitance was cancelled and series resistance was com-
pensated for (> 80%). Data were low-pass-filtered at
2 kHz, sampled at 10 kHz, and acquired with the pulse
protocol. The liquid junction potential between internal
and external solutions was −5 mV on average and was
used to correct for the recorded membrane potential.
The pipette solution was composed of the following (in
mM): 140 CsCl, 10 NaCl, 1 MgCl•6H2O, 0.5 CaCl2, 5
EGTA, 10 HEPES and 2 Na2-ATP, and adjusted topH 7.4 with CsOH (320 mosm). Extracellular solution
contained the following (in mM): 120 NaCl, 5 KCl, 30
TEA-Cl, 10 Glucose, 10 HEPES, 10 4-AP, 2 CaCl2, 0.1
CdCl2, 2 MgCl•6H2O and 0.0005 TTX, and adjusted to
pH 7.4 with NaOH (310 mosm). The TEA-Cl, CdCl2
and TTX were used to inhibit endogenous K+, Ca2+ and
TTX-s sodium currents, respectively.
Drugs and chemicals used
AMI, TTX, trypsin, L-glutamine, poly-L-lysine, HEPES,
EGTA, TEA-Cl, Na2-ATP, CdCl2, CsOH and CsCl were
purchased from Sigma. Other chemical reagents used
were of analytic grade. AMI was prepared as a 100 mM
stock solution in distilled water and further dilutions
were made fresh in extracellular solution on the day of
each experiment. AMI was continuously administered
(approximately 1 mL/min) to the cells via superfusion
polyethylene tubes during the recording procedure.
Data analysis
Data were analyzed using pCLAMP 10.0 (Axon
instruments, USA) and Origin 7.5 (Microcal Software,
Northampton, MA, USA) software. Concentration-
response curves were fit to the Hill function: Idrug/Icontrol =
1/[1 + (C/IC50)
H], where Idrug/Icontrol is fractional blockade,
C is the drug concentration, IC50 is the drug concentra-
tion that causes 50% blockade, and H is the Hill coeffi-
cient. The voltage-activation curves and the steady-state
inactivation curves were fit with the Boltzmann function:
I/Imax = 1 − 1/(1 + exp[(Vm −V0.5 act)/k)] and I/Imax = 1/
(1 + exp[(Vm −V0.5 inact)/k)], respectively, where Imax is
maximal current, Vm is the prepulse voltage, V0.5 is the
voltage generating half maximal current, and k is the slope
factor of the curves. All data are presented as the mean ±
SEM. Statistical significance was assessed using SPSS 13.0
(SPSS Inc, Chicago, IL). Student’s t-test analysis was used
to assess differences between means from two groups.
One-way ANOVA of variance followed by Dunnett post-
testing was performed to assess differences than two more
groups. A P value < 0.05 was considered to be significant.
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